Abstract

Fibroblasts in the tumor microenvironment have been proven to actively participate in tumor progression; they can be “educated” by cancer cells acquiring an activated state and, as such, are identified as cancer-associated fibroblasts (CAFs); CAFs, in turn, remodel tumor stroma to be more advantageous for cancer progression by modulating several processes, including angiogenesis, immunosuppression, and drug access, presumably driving the chemoresistance. That is why they are believed to hamper the response to clinical therapeutic options. The communication between cancer cells and fibroblasts can be mediated by extracellular vesicles (EVs), composed of both exosomes (EXOs) and microvesicles (MVs). To verify the role of different subpopulations of EVs in this cross-talk, a nearly pure subpopulation of EXO-like EVs and the second one of mixed EXO- and MV-like EVs were isolated from ovarian cancer cells and administered to fibroblasts. It turned out that EVs can activate fibroblasts to a CAF-like state, supporting their proliferation, motility, invasiveness, and enzyme expression; EXO-like EV subpopulation seems to be more efficient in some of those processes, suggesting different roles for different EV subpopulations. Moreover, the secretome of these “activated” fibroblasts, composed of both soluble and EV-associated molecules, was, in turn, able to modulate the response of bystander cells (fibroblasts, tumor, and endothelial cells), supporting the idea that EVs sustain the mutual cross-talk between tumor cells and CAFs.

Highlights

  • The term “extracellular vesicles” (EVs) is used to describe all spherical and membrane-enclosed vesicles released into the extracellular space by both normal and tumor cells [1]

  • The different subpopulations of EVs show a different ability to stimulate these processes: the EXO-like EVs rather than the mixed population of EXO- and MV-like EVs seem to be more efficient in some activation processes. These findings suggest that EVs, EXOs, can be considered pivotal targets of novel anticancer therapies to hamper fibroblast activation

  • Such morphological changes were visible in Normal human dermal fibroblasts (NHDF) treated with ovarian cancer EVs30′ and EVs18h starting after 72 h at the beginning of treatment (Figure 1), whilst untreated fibroblasts exhibit typical elongated and spindle-shaped morphology, some NHDF30′ and NHDF18h underwent a morphological change, acquiring the typical morphology of activated fibroblasts (NHDF30′ and NHDF18h are, respectively, NHDF treated with EVs30′ and EVs18h): they appeared very spread with many visible stress-contractile fibers inside the cytoplasm

Read more

Summary

Introduction

The term “extracellular vesicles” (EVs) is used to describe all spherical and membrane-enclosed vesicles released into the extracellular space by both normal and tumor cells [1]. When their size and cellular origin are considered, it is possible to distinguish three subpopulations of EVs: exosomes (EXOs), microvesicles (MVs), and apoptotic bodies (ABs) [2]. EVs are considered as an intercellular communication mechanism acting as molecular shuttles packaged with a bioactive cargo of proteins, lipids, and nucleic acids that are used by cells to interact with the neighboring ones to modulate their environment [3, 4]; once released, they can interact with target cells, releasing their content into extracellular space following EV lysis, interacting with their receptors, by fusion, or other mechanisms yet to be identified [3,4,5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call